Evidence map›Paper›PMID 32593259›Full record

ArticleAdvances in gerontology = Uspekhi gerontologii2020

[Theory and practice of aging upon COVID-19 pandemic.]

A G Golubev, A V Sidorenko

Abstract read
In one paragraph

Article in Advances in gerontology = Uspekhi gerontologii, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. COVID-19: A Challenge to Physiology of Aging.Frontiers in physiology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

A G GolubevN.N.Petrov National Medical Research Center of Oncology, 68 Leningradskaya str., Pesochnyi, St. Petersburg 197758, Russian Federation, e-mail: lxglbv@rambler.ru.
A V SidorenkoEuropean Centre for Social Welfare Policy and Research, Berggasse 17, 1090 Vienna, Austria, e-mail: sidorenko.alexandre@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Never before in history, aging was such a significant factor for epidemics as it is now for the current COVID-19 pandemic, which features a drastic shift of mortality towards older ages. Our analysis of data on COVID-19-related mortality in Spain, Italy, and Sweden has shown that, in the range of 30 to 90 years of age, each dependency of the logarithm of mortality upon age is linear, and all regression lines are strictly parallel to those related to the total mortality in accordance with the Gompertz law. In all cases, irrespective of the stage and place of epidemic, mortality doubling time in this age range is close to 7,5 years. The rates of being infected with the SARS-CoV-2 coronavirus and of being diagnosed due to the symptomatic manifestations of the infection are dependent on age to a far lesser degree. With account for these observations, three messages are put forth: 1) Older persons are the principal victims of both SARS-CoV-2 and measures undertaken to control its spread; 2) Older persons are not the principal driving force of SARS-CoV-2 spread; 3) Older persons can and should be engaged in combating the pandemic and its consequences; however, not via selective social distancing and other discriminative measures. People aged over 65 years constitute a significant part of the current population. They have specific interests and needs, which deserve no less respect than those of any other age group. This includes the right for the quality of life that remains sustained under the emergency conditions. Since the prospects for controlling the SARS-CoV-2 are dubious, those in charge of decisions concerning «people aged above 65» should mind that currently, unlike in the medieval ages, 65+ is the individual future of almost everyone.

Indexed as

AgingPandemicsAgedCoronavirus InfectionsCOVID-19HumansPneumonia, ViralSocial TheoryagingCOVID-19epidemiologygeriatricsgerontology

Identifiers

PMID32593259
PMCPMC7724777

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.